Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Hefty Hirudoid Prescriptions Now under Scrutiny, Chuikyo Members at Odds over Restrictions
November 6, 2017
- Heads of Medicines Regulatory Agencies Agree to Promote Global Harmonization to Enable Use of Real World Data as Evidence
November 2, 2017
- Payer Rep Calls on Govt to Promote Use of Formularies at Hospitals to Ensure Use of Cheaper Option: Chuikyo
November 2, 2017
- Clinical Research Review System Based on Clinical Research Law to Start at Minimum of 11 Locations: MHLW
November 2, 2017
- PM Abe Watchful of Reward for Me-Too Drugs, CEFP Minutes Reveal
November 1, 2017
- Chuikyo Moots Possible Expansion of “Essential Drugs”; MHLW Pitches Antibacterial Eye Drops
October 30, 2017
- Kamoya Leaves Chuikyo as Industry Rep, Lauds Breakthrough for Essential Drug Rule
October 30, 2017
- Opdivo Could Face Deeper Cut with Revision of Dosage-Change Re-Pricing Rule; Keytruda Could Be Affected Too
October 30, 2017
- CEFP Kicks Off FY2018 Budget Debate with Major Focus on Scope of Off-Year Price Survey, Revision
October 27, 2017
- MHLW Issues Notification Revising GPSP Ordinance in Response to Medical Information Database
October 27, 2017
- Scrap Price Maintenance Premium, or Limit Scope of Products: MOF
October 26, 2017
- Chuikyo Proposes 5% ICER Deduction for Each Ethical/Societal Criteria Met
October 26, 2017
- Chuikyo OKs “5 Million Yen,” “10 Million Yen” Thresholds for 3-Segment CEA Price Adjustment Model
October 26, 2017
- Payer Rep Insists CEA-Based Price Hike “Not an Option,” MHLW Wants “Grounds” for That Argument: Chuikyo
October 26, 2017
- Consumer Representative on MHLW Advisory Panel Resigns after Taking Regular Payments from Megmilk Snow Brand
October 26, 2017
- Patient Dies due to Mix-Up of Lixiana, Rifxima; PMDA, Companies Issue Warning Statement
October 26, 2017
- Cabinet Approves 5-Year Plan to Promote Anticancer Measures
October 26, 2017
- Sanofi’s Dupilumab, Chugai’s PD-L1 Inhibitor and More Up for MHLW Panel Review on Nov. 6
October 25, 2017
- Conditional Early Approval System Gets Underway: MHLW
October 23, 2017
- LDP Healthcare Big Names Handily Nab Seats in Snap Election
October 23, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…